We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Antisense oligonucleotides to class III beta-tubulin sensitize drug-resistant cells to Taxol.
- Authors
Kavallaris, M; Burkhart, C A; Horwitz, S B
- Abstract
A major impediment to the successful use of Taxol in the treatment of cancer is the development of drug resistance. The major cellular target of Taxol is the microtubule that is comprised of alpha- and beta-tubulin heterodimers. Binding sites for Taxol have been delineated on the beta-tubulin subunit that has six isotypes. We have recently described increased expression of the brain-specific human class III beta-tubulin isotype, encoded by the Hbeta4 gene, in both Taxol-resistant ovarian tumours and non-small-cell lung cancer cell lines. To evaluate directly the role of the class III beta-tubulin isotype in mediating Taxol resistance, antisense phosphorothioate oligodeoxynucleotides (ODN) targeted against various regions of the Hbeta4 gene have been designed and examined for their efficacy in reducing Hbeta4 gene and protein expression. Taxol-resistant lung cancer cells, A549-T24, which are 17-fold resistant to Taxol and display a fourfold increase in Hbeta4 expression compared to the parental A549 cells, were treated with 1 microM antisense ODNs. Two ODNs, AS1 and AS3, were found to reduce mRNA expression by 40-50%, as determined by reverse transcription polymerase chain reaction. A concentration-dependent reduction in Hbeta4 mRNA expression was demonstrated with AS1 ODN. Immunofluorescence staining of cells treated with AS1 ODN revealed a decrease in class III protein expression which corresponded to a 39% increase in sensitivity to Taxol (P < 0.005). These findings support an important role for Hbeta4 (class III) beta-tubulin expression in Taxol resistance and have potential implications for the treatment of Taxol-resistant tumours.
- Subjects
PACLITAXEL; DRUG resistance; CANCER treatment; RNA metabolism; NUCLEOTIDE metabolism; ANTINEOPLASTIC agents; COMPARATIVE studies; DRUG resistance in cancer cells; DOSE-effect relationship in pharmacology; FLUORESCENT antibody technique; LUNG cancer; LUNG tumors; RESEARCH methodology; MEDICAL cooperation; NERVE tissue proteins; NUCLEOTIDES; PROTEINS; RESEARCH; EVALUATION research; CANCER cell culture; CHEMICAL inhibitors; PHARMACODYNAMICS
- Publication
British Journal of Cancer, 1999, Vol 80, Issue 7, p1020
- ISSN
0007-0920
- Publication type
journal article
- DOI
10.1038/sj.bjc.6690507